Equities

Aditxt Inc

ADTX:NAQ

Aditxt Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.3826
  • Today's Change-0.015 / -3.87%
  • Shares traded7.30m
  • 1 Year change-97.87%
  • Beta0.9899
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast

The one analyst offering a 12 month price target expects Aditxt Inc share price to rise to 61.00 in the next year from the last price of 0.3826.
High15,843.5%61.00
Med15,843.5%61.00
Low15,843.5%61.00

Earnings history & estimates in USD

Earnings forecasts are not available for Aditxt Inc. On Aug 14, 2024, Aditxt Inc reported 2nd quarter 2024 losses of -- per share.
Average growth rate-3.57%
Aditxt Inc reported annual 2023 losses of -107.21 per share on Apr 16, 2024.
Average growth rate+46.20%
More ▼

Revenue history & estimates in USD

Revenue forecasts are not available for ADiTx Therapeutics, Inc..
Average growth rate-38.88%
ADiTx Therapeutics, Inc. had revenues for the full year 2023 of 645.00k. This was 30.94% below the prior year's results.
Average growth rate+379.29%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.